OP-ED: FUNDING ROADBLOCKS CREATING DIGITAL HEALTH INEQUITY Beyond just clinical: Making the case for a pivot in reimbursement by Australian Government
With
Helen Souris,
CEO and Executive Director
Cardihab &
Board Member
Medical Technology Association of Australia (MTAA)
OP ED SEGMENT
Filmed in Sydney | June 2026
Helen Souris, CEO and Executive Director of Cardihab and Chair of the Digital Health Advisory Group at the Medical Technology Association of Australia (MTAA), highlights the significant gap in cardiac rehabilitation access across Australia. Despite the proven benefits of cardiac rehabilitation in improving survival, quality of life, and reducing hospital admissions, around 80% of eligible patients do not receive this care, with access rates even lower in regional and rural communities.
Cardihab was established as a digital health company originating from CSIRO research and has spent the past decade developing a digital therapeutic solution for cardiac rehabilitation.
Delivered through a clinically supervised software platform, the program enables patients to access rehabilitation remotely, removing barriers associated with travel and face-to-face attendance. The platform is registered with the Therapeutic Goods Administration (TGA) as a Class IIa medical device, reflecting its compliance with rigorous clinical and regulatory standards.
Over ten years, Cardihab has built a substantial evidence base, including randomised controlled trials and real-world studies. Independent research has demonstrated improvements in patient outcomes, quality of life, and cost-effectiveness, with the program outperforming traditional alternatives in most evaluated scenarios. As a result, the majority of private health insurers now support access to the platform, while statewide implementation has been achieved through partnerships such as the Tasmanian Health Service.
Despite these successes, Souris identifies funding as the primary barrier to broader adoption within the public health system. She argues that Australia already possesses the technology required to support the government’s digital health ambitions and that sustainable funding and reimbursement mechanisms are now needed to enable widespread access to evidence-based digital therapeutics and remote patient care solutions.
Source: Adapted from transcript
Media access credit: Medical Technology Association of Australia (MTAA)
Note: Op Ed segments are opinions and comments on policies. They should be watched for awareness purposes only, and do not necessarily reflect the views held by Australian Health Journal.
-
Spinal implant technology eyes global opportunity
Adelaide, South Australia wants to let the secret out, and be known as hub for medical devices, pharmaceuticals, biotechnology, and digital health. It boasts world-class research institutions, such as the University of Adelaide and SAHMRI, fostering innovation and collaboration. The city’s supportive government policies provide incentives, grants, and streamlined regulations for businesses. Adelaide’s skilled workforce, renowned for its expertise in health sciences, offers a talent pool to drive industry growth. Additionally, the city’s strategic location, advanced infrastructure, and strong healthcare ecosystem make it an ideal base for development, manufacturing, and market access, attracting companies in these sectors.
-
Getting the conversation going on the connection between oral health and chronic conditions
Dr. Carol Tran is an Oral Health Therapist and co-founder of Oral Health Home, an organisation focused on innovative, prevention-oriented oral health education and outreach. She is a Past President of Dental Hygienists Association of Australia (DHAA) and currently is the Scientific Program Chair, for upcoming congress in October 2025, for the newly formed Oral Health Association of Australia (OHAA).
-
ICTD: Clinical trials in regional, rural and remote Australia
To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leaving up to 20th May. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials. The first segment is an example of how in-person clinical trial access has improved for regional, rural and remote communities.
